11^th European Chemistry Congress June 21-22, 2021 Barcelona, Spain

Daniel T Gryko obtained his PhD from the Institute of Organic Chemistry of the Polish Academy of Sciences in 1997, under the supervision of Prof. J. Jurczak. After a Postdoctoral stay with Prof. J. Lindsey at North Carolina State University (1998–2000), he started his independent career in Poland. He became Full Professor in 2008. The same year he received the Society of Porphyrins and Phthalocyanines Young Investigator Award. His current research interests are focused on the synthesis of various functional dyes as well as on two-photon absorption, artificial photosynthesis, excited-state intramolecular proton transfer and fluorescence probes.

Research interests are focused on the synthesis of various functional dyes as well as on two-photon absorption, artificial photosynthesis, excited-state intramolecular proton transfer and fluorescence probes.

Silvia Antonia Brandán is a Faculty Biochemistry, Chemistry and Pharmacy, in Inorganic Chemistry Institute, University National of Tucumán (UNT), Tucumán, Argentina. She is Graduated in Chemistry (UNT); Chemical Engineer (UNT); PhD in Chemistry (UNT); Post-Doctorate in Alicante University, Spain. She is the Titular Professor of General Chemistry and Director of the Inorganic Chemistry Institute. She is the Editor Journal of Molecular Structure.

Biochemistry, Chemistry and Pharmacy, in Inorganic Chemistry Institute

Dr. Feng is an expert in biochemistry and biophysics of metalloproteins. His laboratory is known for its use of multidisciplinary approaches to study molecular mechanisms of metalloproteins in medicine and toxicology. The laboratory is active in the use of cutting-edge approaches across the broad fields of chemistry, biochemistry, physics and chemical biology (including laser flash photolysis, pulsed EPR, computational chemistry and site-directed mutagenesis). The goal is to understand what the function of a biological relevant metal site is, how it goes about to achieve its function, and what factors dictate its function. His current primary research focus is on regulation mechanism of nitric oxide synthase (NOS), a flavo-hemoprotein responsible for biosynthesis of nitric oxide (NO), a ubiquitous signaling and effector molecule in mammalian cell biology. Recent studies of NOS proteins by Dr. Feng demonstrate that domain motions and interdomain docking play an important role in NOS isoform function by modulating key electron transfer processes. Molecular mechanisms of NOS regulation, once fully understood, are potentially key targets for development of selective new pharmaceuticals for treating a wide range of diseases that currently lack effective treatments. Dr. Feng has published more than 70 scientific manuscripts, is an active NIH reviewer and also serves as referee for NSF, AHA, the French National Research Agency and the Italian Ministry of Health.

Biochemistry, Biophysics and toxicology

Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name of Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.

His research interest focuses on Cancer.

Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name of Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.

His research interest focuses on Cancer.

1978 and 1999 has completed his Ph.D and D.Sci. at the ages of 33 and 54 years from Zelinsky Instiute of Organic Chemistry, Moscow, Russia and Durmishidze Institute of Biochemistry and Biotechnology, Tbilisi, Georgia, respectively. 2006 up to date he is the head of laboratory of plant biopolymers at the Tbilisi State Medical University Institute of Pharmacochemistry. 1996 and 2002 he has been a visiting scientist at Utrecht University (faculty of pharmacy), The Netherlands, by University Scholarship and The Netherlands organization for scientific research (NWO) Scholarship Scientific Program, respectively. He has published more than 80 papers in reputed journals.

Biochemistry, biotechnology,biopolymers, Pharmacochemistry and pharmacy